
1/33



1-(Propoxymethyl)- maleimide

MIRA-1


Fig. 1A



2,2-bis(hydroxymethyl)-1-azabicyclo[2,2,2]octan-3-one

PRIMA-1


Fig. 1B



growth suppression, %

MEDICAMENI OSEFOL IN INCATING MOTANT FOO MEDI


-4/33




growth suppression, %


-ig. 2A













7/33



days after treatment

Fig. 2C







Saos-2-His-273


cell number x 100

Fig. 2C


days after treatment









11/33






12/33






13/33



14/33

. ARING

Fig. 3C




after heating at 37°C for 30 min

% of PAb 1620 epitope remaining

Fig. 4A


16/33



% of 1620 epitope remaining


Fig. 4A

17/33



after heating at 37°C for 30 min


% of PAb 1620 epitope remaining



after heating at 37°C for 30 min

% of PAb 240 epitope remaining


18/33



after heating at 37°C for 30 min


% of PAb 240 epitope remaining

DOCKET NO.: 1505-1052
INVENTOR: VLADIMIR BYKOV ET AL.
FILING DATE: AUGUST 23, 2004
TITLE: USE OF LOW MOLECULAR WEIGHT COMPOUNDS FOR PREPARING
A MEDICAMENT USEFUL IN TREATING MUTANT P53 MEDIATED DISEASES




after heating at 37°C for 30 min

% of DO-I epitope remaining





% of PAb DOI epitope remaining




.21/33

















Fig. 7





.27/33







PRIMA-1,50µM 20h












untreated


28/33














Hoechst








Fig. 9C




EGFP

Hoechst




Æ




B

	Dox-			:Dox+		
	control	PRIMA-1	MIRA-1	control	PRIMA-1	MIRA-1
MDM-2			"		-	
p21						


С






tumor volume, mm³

ig. 11



growth suppression, %



growth suppression, %

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:
☐ BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
DELURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
☐ LINES OR MARKS ON ORIGINAL DOCUMENT
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
OTHER:

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.